Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

You may be eligible if

• Histologically confirmed solid tumors, including CNS tumors or lymphoma
• * Histological confirmation not required for the following diagnoses
• * Intrinsic brain stem tumors
• * Optic pathway gliomas
• * Pineal tumors and elevations of cerebral spinal fluid or serum tumor markers, including alpha-fetoprotein or beta-human chorionic gonadotropin, allowed
• * Relapsed or refractory disease
• Must have measurable or evaluable tumor
• No known curative therapy or therapy proven to prolong survival with an acceptable quality of life
• Karnofsky performance status (PS) 60-100% for patients \> 16 years of age OR Lansky PS60-100% for patients ≤ 16 years of age
• * Neurologic deficits inpatients with CNS tumors must have been relatively stable for a minimum of 1week
• * Patients who are unable to walk because ofparalysis, but who are up in a wheelchair, will be considered ambulatory for thepurpose of assessing the performance score
• ANC ≥ 1,000/μL
• Platelet count ≥ 100,000/μL (transfusion independent, defined as not receiving platelet transfusions within the past 7 days)
• * Patients with known bone marrow metastatic disease allowed provided they meet the blood count criteria and are not known to be refractory to platelet transfusion
• Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)
• * Patients with known bone marrow metastatic disease allowed provided they meet the blood count criteria and are not know to be refractory to RBC or platelet transfusion
• Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on age and/or gender as follows:
• * 0.6 mg/dL (1 to \< 2 years of age)
• * 0.8 mg/dL (2 to \< 6 years of age)
• * 1.0 mg/dL (6 to \< 10 years of age)
• * 1.2 mg/dL (10 to \< 13 years of age)
• * 1.5 (male) or 1.4 (female) (13 to \< 16 years of age)
• * 1.7 (male) or 1.4 (female) ( ≥ 16 years of age)
• Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 times upper limit ofnormal
• ALT ≤ 110 U/L
• Serum albumin ≥ 2 g/dL
• QTc interval ≤ 450 milliseconds
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Must be able to swallow capsules or liquids
• Able to comply withthe safety-monitoring requirements of the study, in the opinion of the investigator
• No peripheral neuropathy ≥ grade 2 within the past 14 days
• No known hypersensitivity to vorinostat or bortezomib
• No uncontrolled infection
• No concurrent enzyme-inducing anticonvulsants
• Must be recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy
• More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea)
• At least 7 days since prior therapy with any of the following:
• * Hematopoietic growth factors
• * Biologic (anti-neoplastic) agent
• * For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur
• * Corticosteroids unless on a stable or decreasing dose
• At least 7 days or 3 half-lives, whichever is longer, since prior monoclonal antibodies
• At least 2 weeks since prior local palliative radiotherapy (small port)
• At least 6 months since prior total-body irradiation therapy, craniospinal radiotherapy, or ≥ 50% of pelvis irradiated
• At least 6 weeks since prior substantial bone marrow radiotherapy
• At least 3 months since prior stem cell transplantation or rescue and no evidence of active graft-vs-host disease
• At least 2 weeks since prior and no concurrent valproic acid
• At least 6 weeks since priorimmunotherapy (e.g., tumor vaccines)
• No prior vorinostat
• No other concurrent investigational drugs or other anticancer agents, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy